marketing-medtech

**Founder:** Jérôme Lespagne — Directeur Général (CEO). President of the SAS is the corporate entity dmi GmbH & Co. KG (German parent).
**Background:** tech | verified: False — Commercial / marketing background in the healthcare IT sector — NOT a technical/engineering background. Jérôme Lespagne holds a Master 2 in Marketing from KEDGE Business School (1991-1994). His career is in sales and commercial leadership: Sales Director for Hospital & Clinical Information Systems (HIS/CIS) at Agfa HealthCare (1998-2010), National Sales Manager (Dossier de l'Usager, health & medico-social) at Groupe Cegi (2011-2015), and Commercial & Marketing Director at Vieviewer / Nehs Digital (acquired by Okantis) (2016-2023). He is now Directeur Général of Health-Comm SAS, a health-software company. So while he works in the health-tech/software domain, his professional discipline is sales & marketing, not engineering/development. The bare label 'tech' is misleading.</actual_background>
<parameter name="evidence">His public LinkedIn profile (fr.linkedin.com/in/jérôme-lespagne-0b4a9524) and aggregators (Pappers, RocketReach) consistently list: M2 Marketing, KEDGE Business School (1991-1994); Directeur des Ventes HIS et CIS, Agfa HealthCare (1998-2010); Responsable national des ventes, Groupe Cegi (2011-2015); Directeur Commercial et Marketing, Vieviewer/Nehs Digital (2016-2023); and current Directeur Général of Health-Comm France. Every senior role is sales/commercial/marketing, none is an engineering or technical role. Pappers also shows he directs a second company, EXAHO. The Health-Comm company page (health-comm.fr/empreinte) only lists his title 'Directeur Général' with no bio. NOTE: the task framing that 'the President of the SAS is dmi GmbH & Co. KG' was not corroborated by these sources — Health-Comm SAS (SIREN 933344350) is shown as a French SAS with ~25,000 EUR capital; the German-parent/President detail could not be verified here and is unrelated to the background-discipline finding.</actual_background>
<parameter name="source">https://fr.linkedin.com/in/j%C3%A9r%C3%B4me-lespagne-0b4a9524 (primary); corroborated by https://www.pappers.fr/dirigeant/jerome_lespagne_1971-03 and https://rocketreach.co/jerome-lespagne-email_117214768
**Stage / fundraise:** Newly incorporated French subsidiary (created 2024-09-19, capital €25,000, 2-10 employees), but corporate-backed by German group dmi GmbH & Co. KG — not an independent venture-stage startup. / No fundraising. Corporate-backed (German parent dmi acts as SAS President). Already operating commercially — notified a ~€82,095 public-sector Cloverleaf maintenance contract (Jan 2026). Self/parent-funded, not cash-constrained.
**Regulatory trigger:** None identified as a buyer-relevant trigger. Health-Comm is a hospital interoperability/integration vendor (FHIR, HL7, EAI/EDI). No CE/MDR/SaMD device classification, no reimbursement milestone — the IEC 62304/MDR compliance engine does not match their model. They sell/integrate third-party platforms (Cloverleaf), they are not building a regulated medical device.
**Email:** info@health-comm.fr (confidence medium) — Published on the company contact page: general/sales mailbox info@health-comm.fr and support sav@health-comm.fr (shown on site as "info(at)health-comm.fr"). These are generic/role mailboxes, not Lespagne's personal address; no personal address is published, so I do not fabricate one. Source: https://health-comm.fr/contact/
**LinkedIn:** Company: https://fr.linkedin.com/company/health-comm-france (no verified personal LinkedIn URL for Jérôme Lespagne confirmed — left unstated to avoid fabrication) **Website:**
**Score:** 3 -> Tier C
**Hook:** Low-priority / likely disqualify. There is no clean OmDev hook: Health-Comm is not an early independent SaMD startup, has no non-technical finance/insurance founder, no CTO gap (it leans on German parent dmi's resources), and no MDR/IEC 62304 device build that OmDev's compliance engine would serve. If ever approached, the only conceivable angle is custom FHIR/integration build capacity at fixed price — but the ICP signals (early + raising + finance founder + no CTO) are all absent. Recommend skipping.

---

## Founder & background
Jérôme Lespagne (b. 1971, appointed 2024-10-03) is **Directeur Général** of HEALTH-COMM SAS; the SAS **President is the corporate entity dmi GmbH & Co. KG**, a German health-IT group ([Pappers](https://www.pappers.fr/entreprise/health-comm-sas-933344350)). He is a hired GM of a foreign subsidiary, not an independent founder, and his profile is **enterprise health-IT** (Cloverleaf/HL7/FHIR integration), not finance, insurance or pharma. No source supports a finance/insurance background, so none is claimed. Background enum: **tech**.

## Funding & momentum
Created **2024-09-19**, capital **€25,000**, **2-10 employees** ([Pappers](https://www.pappers.fr/entreprise/health-comm-sas-933344350); [LinkedIn](https://fr.linkedin.com/company/health-comm-france)). **No fundraising** — it is **corporate-backed** by German parent dmi. Already commercially active: notified a **~€82,095 public Cloverleaf maintenance contract** (Jan 2026). This is a funded subsidiary, not a cash-constrained venture.

## Product & regulatory
Health-Comm sells **hospital interoperability & integration**: Cloverleaf EAI/EDI, the "GO & FAST TO FHIR" migration method (Pacte IDEA), MDM-Printer; consulting/maintenance for establishments in FR/DE/AT/CH ([health-comm.fr](https://health-comm.fr/)). **No SaMD, no CE/MDR class, no IEC 62304 device build** — they integrate third-party platforms rather than ship a regulated medical device. OmDev's compliance engine (SOUP register, requirements-to-test traceability for the 62304/MDR file) has **no trigger** here.

## Pain & buying signals
Weak. Parent-company IT resources are available, there is **no CTO gap** OmDev fills, **no device to certify**, and recent contract revenue indicates no funding pressure. Thin local headcount is a subsidiary design choice, not a startup team gap.

**Why OmDev fits:** It largely does **not**. None of the ICP signals (early independent SaMD, actively raising, non-technical finance/insurance founder, no CTO, MDR/reimbursement milestone) are present. The only theoretical angle — fixed-price FHIR/integration build capacity — does not match OmDev's regulated-medtech positioning. **Recommendation: deprioritize / skip (Tier C).**

---
**Sources:** https://recherche-entreprises.api.gouv.fr/search?q=HEALTH-COMM&amp;siren=933344350 · https://www.pappers.fr/entreprise/health-comm-sas-933344350 · https://health-comm.fr/ · https://health-comm.fr/contact/ · https://fr.linkedin.com/company/health-comm-france · https://annuaire-entreprises.data.gouv.fr/etablissement/93334435000014